Novartis AG (NVS)
Automate Your Wheel Strategy on NVS
With Tiblio's Option Bot, you can configure your own wheel strategy including NVS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVS
- Rev/Share 29.269
- Book/Share 23.2357
- PB 6.5109
- Debt/Equity 0.7224
- CurrentRatio 0.8812
- ROIC 0.1851
- MktCap 287550186953.0
- FreeCF/Share 8.8572
- PFCF 16.8562
- PE 20.0535
- Debt/Assets 0.2985
- DivYield 0.0219
- ROE 0.3412
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | NVS | Citigroup | -- | Buy | -- | -- | Jan. 27, 2026 |
| Upgrade | NVS | Barclays | Underweight | Equal Weight | -- | -- | Jan. 6, 2026 |
| Upgrade | NVS | JP Morgan | Neutral | Overweight | -- | -- | Dec. 8, 2025 |
| Upgrade | NVS | Morgan Stanley | Equal Weight | Overweight | -- | -- | Dec. 3, 2025 |
| Upgrade | NVS | BofA Securities | Neutral | Buy | -- | -- | Nov. 25, 2025 |
| Downgrade | NVS | Goldman | Neutral | Sell | -- | $118 | Sept. 12, 2025 |
| Upgrade | NVS | Morgan Stanley | Underweight | Equal Weight | -- | $123 | Aug. 8, 2025 |
| Downgrade | NVS | UBS | Buy | Neutral | -- | -- | Feb. 13, 2025 |
| Initiation | NVS | Morgan Stanley | -- | Underweight | -- | -- | Feb. 12, 2025 |
| Upgrade | NVS | Deutsche Bank | Hold | Buy | -- | -- | Feb. 4, 2025 |
News
Here's Why Novartis (NVS) is a Strong Momentum Stock
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Novartis Invests $7.5M to Promote Early Prostate Cancer Testing in Vulnerable Communities
Published: February 20, 2025 by: CNBC Television
Sentiment: Positive
Novartis commits $7.5 million to the "Blitz the Barriers" campaign, aiming to raise awareness and encourage early testing for prostate cancer in vulnerable communities.
Read More
Novartis: Just What The Doctor Ordered
Published: February 14, 2025 by: Seeking Alpha
Sentiment: Positive
Novartis' robust drug pipeline and strong financials, including an AA- credit rating, support an 11% annual return expectation by 2027. The company's diverse blockbuster portfolio and strategic cost management drove a 15.1% sales increase and 29% EPS growth in Q4 2024. Novartis' shares are undervalued by 11%, offering a 33% cumulative return potential through 2027, with a secure and growing 3.5% dividend yield.
Read More
Novartis to buy Anthos Therapeutics in $3.1bn deal
Published: February 11, 2025 by: Proactive Investors
Sentiment: Positive
Novartis AG (ADR) (NYSE:NVS) has agreed to buy Anthos Therapeutics in a deal worth up to $3.1 billion. The Swiss drugmaker will pay $925 million upfront, with potential milestone payments of $2.15 billion.
Read More
Novartis agrees to acquire Anthos for up to $3.1 bln
Published: February 11, 2025 by: Reuters
Sentiment: Positive
Novartis has agreed to acquire Anthos Therapeutics, a developer of a new generation of blood thinners it launched five years ago with backing from the Swiss pharmaceutical giant.
Read More
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral
Basel, February 11, 2025 – Novartis today announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical company with abelacimab, a late-stage medicine in development for the prevention of stroke and systemic embolism in patients with atrial fibrillation. The transaction, which is subject to customary closing conditions, is fully in line with Novartis' growth strategy and therapeutic area focus, leveraging the company's strength and expertise in the cardiovascular area.
Read More
About Novartis AG (NVS)
- IPO Date 1996-11-07
- Website https://www.novartis.com
- Industry Drug Manufacturers - General
- CEO Vasant Narasimhan
- Employees 75883